Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Pediatric Long-Term Follow-up and Rollover Study
Back

Pediatric Long-Term Follow-up and Rollover Study

Not Recruiting

Open to: ALL

Age: 1.0 - 99.0

Sutton London London Liverpool

Medical Conditions

Diffuse Astrocytoma
Anaplastic Astrocytoma
Astrocytoma
Oligodendroglioma, Childhood
Anaplastic Oligodendroglioma
Glioblastoma
Pilocytic Astrocytoma
Giant Cell Astrocytoma
Pleomorphic Xanthoastrocytoma
Anaplastic Pleomorphic Xanthoastrocytoma
Angiocentric Glioma
Chordoid Glioma of Third Ventricle
Gangliocytoma
Ganglioglioma
Anaplastic Ganglioglioma
Dysplastic Gangliocytoma of Cerebrellum
Desmoplastic Infantile Astrocytoma and Ganglioglioma
Papillary Glioneuronal Tumor
Rosette-forming Glioneuronal Tumor
Central Neurocytoma
Extraventricular Neurocytoma
Cerebellar Liponeurocytoma
Neurofibromatosis Type 1

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2019 Nov 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : dabrafenib oral, twice daily

Intervention Arm Group : Dabrafenib and/or trametinib;

Intervention Type : DRUG
Intervention Description : trametinib oral, once daily

Intervention Arm Group : Dabrafenib and/or trametinib;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Novartis Investigative Site
    Sutton
    Surrey
    SM2 5PT
  • Novartis Investigative Site
    London
    WC1N 3JH
  • Novartis Investigative Site
    London
    NW1 2BU
  • Novartis Investigative Site
    Liverpool
    L12 2AP


The study is sponsored by Novartis Pharmaceuticals



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03975829
Last updated 12 February 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top